Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aimmune Therap (NQ: AIMT )

34.49 USD UNCHANGED
Last Price Updated: 7:11 PM EDT, Oct 12, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aimmune Therap

< Previous 1 2 3 4 5 6 7 Next >
Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers
Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on 
From Business Wire News Releases
Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference 
From Business Wire News Releases
Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights
Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights 
From Business Wire News Releases
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights 
From Business Wire News Releases
Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent Health
Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent Health 
From Business Wire News Releases
Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations
Aimmune Appoints Narinder Singh as Executive Vice President of Technical Operations 
From Business Wire News Releases
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy
New Two-Year PALFORZIA™ Data Show On-going Safety and Efficacy and Continued Immunomodulation in Patients with Peanut Allergy 
From Business Wire News Releases
New Data Show Patients Are Highly Satisfied With and Confident in the Efficacy of Daily Treatment With PALFORZIA™ After Nine Months
New Data Show Patients Are Highly Satisfied with and Confident in the Efficacy of Daily Treatment with PALFORZIA™ After Nine Months 
From Business Wire News Releases
Aimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
Aimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference 
From Business Wire News Releases
New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 Congress
New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented 
From Business Wire News Releases
Largest European Quantitative Study on Peanut Allergy Confirms Significant Need, Burden and Psychosocial Impact of Peanut Allergy on Allergic Individuals and their Caregivers
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced that findings from APPEAL-1... 
From Business Wire News Releases
Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference
Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference 
From Business Wire News Releases
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights 
From Business Wire News Releases
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational Highlights 
From Business Wire News Releases
Aimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference
Aimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference 
From Business Wire News Releases
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy
Aimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut Allergy 
From Business Wire News Releases
Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability and Continued Immunomodulation After 18 and 24 Months of Treatment
Aimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability 
From Business Wire News Releases
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational Highlights 
From Business Wire News Releases
Aimmune Therapeutics to Present at Upcoming Investor Conferences
Aimmune Therapeutics to Present at Upcoming Investor Conferences 
From Business Wire News Releases
Aimmune to Present New Clinical Data at AAAAI Annual Meeting
Aimmune to Present New Clinical Data at AAAAI Annual Meeting 
From Business Wire News Releases
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational Highlights
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational 
From Business Wire News Releases
Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that Nestlé Health... 
From Business Wire News Releases
Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it has obtained an exclusive worldwide... 
From Business Wire News Releases
FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the U.S. Food and... 
From Business Wire News Releases
Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Aimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference 
From Business Wire News Releases
Aimmune to Participate in Three Upcoming Investor Conferences
Aimmune to Participate in Three Upcoming Investor Conferences 
From Business Wire News Releases
New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study without a Food Challenge
New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study 
From Business Wire News Releases
Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments
Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments 
From Business Wire News Releases
New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots
New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots 
From Business Wire News Releases
AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data
AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X